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Preclinical PET studies of β-amyloid (Aβ) accumulation are of growing importance,
but comparisons between research sites require standardized and optimized methods
for quantitation. Therefore, we aimed to evaluate systematically the (1) impact of an
automated algorithm for spatial brain normalization, and (2) intensity scaling methods
of different reference regions for Aβ-PET in a large dataset of transgenic mice. PS2APP
mice in a 6 week longitudinal setting (N = 37) and another set of PS2APP mice at
a histologically assessed narrow range of Aβ burden (N = 40) were investigated by
[18F]-florbetaben PET. Manual spatial normalization by three readers at different training
levels was performed prior to application of an automated brain spatial normalization and
inter-reader agreement was assessed by Fleiss Kappa (κ). For this method the impact
of templates at different pathology stages was investigated. Four different reference
regions on brain uptake normalization were used to calculate frontal cortical standardized
uptake value ratios (SUVRCTX/REF), relative to raw SUVCTX. Results were compared
on the basis of longitudinal stability (Cohen’s d), and in reference to gold standard
histopathological quantitation (Pearson’s R). Application of an automated brain spatial
normalization resulted in nearly perfect agreement (all κ ≥ 0.99) between different
readers, with constant or improved correlation with histology. Templates based on
inappropriate pathology stage resulted in up to 2.9% systematic bias for SUVRCTX/REF. All
SUVRCTX/REF methods performed better than SUVCTX both with regard to longitudinal
stability (d ≥ 1.21 vs. d = 0.23) and histological gold standard agreement (R ≥ 0.66
vs. R ≥ 0.31). Voxel-wise analysis suggested a physiologically implausible longitudinal
decrease by global mean scaling. The hindbrain white matter reference (Rmean = 0.75)
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was slightly superior to the brainstem (Rmean = 0.74) and the cerebellum (Rmean =
0.73). Automated brain normalization with reference region templates presents an
excellent method to avoid the inter-reader variability in preclinical Aβ-PET scans.
Intracerebral reference regions lacking Aβ pathology serve for precise longitudinal in vivo
quantification of [18F]-florbetaben PET. Hindbrain white matter reference performed best
when considering the composite of quality criteria.
Keywords: Alzheimer’s disease, β-amyloid, [18F]-florbetaben, small animal PET, reference region, brain
normalization
INTRODUCTION
The steadily growing number of patients suffering from
Alzheimer’s disease (AD) will place a great burden on healthcare
systems in the coming decades, baring development of an
effective intervention therapy (Schneider, 2013). Molecular
imaging of β-amyloid (Aβ) with positron emission tomography
(PET) has given new insight into the progression of AD
pathology and has entered clinical diagnostic use (Johnson
et al., 2013). Furthermore, PET imaging is increasingly used for
detecting cerebral amyloidosis in transgenicmousemodels of AD
(Manook et al., 2012; Rominger et al., 2013). Small animal PET
studies of longitudinal design afford monitoring of the rate of
β-amyloid accumulation, and present the possibility of testing
interventions for attenuating plaque formation.
Preclinical brain PET imaging frequently suffer from
shortcomings such as underpowered study groups, reader
dependence of endpoints, varying approaches to data analysis,
and inadequate blinding of investigators to treatment groups
(Jucker, 2010). Automated template-based normalization of
rodent brain to standard coordinates, in analogy to standard
methods for analysis of human PET data, has the potential
to minimize biases from reader dependence and imperfect
blinding, although the reliability of such approaches has yet
to be systematically investigated for preclinical Aβ-PET. In
particular, the choice of the optimal template for automated
spatial normalization of Aβ-PET images may be influenced
by pathological features of the particular AD mouse model
(Rohlfing et al., 2009). Since this issue has not hitherto been
raised in preclinical Aβ-PET imaging, we planned to validate an
automated, user-independent approach for spatial normalization
by comparing binding results from readers at different training
levels before and after normalization, with histopathological
examination of fibrillar Aβ as the gold standard. Furthermore, we
objected to study the influence of template selection at different
pathology stages on the automated spatial normalization of
mouse brain Aβ-PET images.
An additional point of contention in preclinical Aβ-
PET concerns the method for image intensity scaling, with
normalization either to the injected dose, or to tracer uptake
in intracerebral reference regions. Just as in human PET
studies with Aβ-PET tracer, the choice of reference regions
is crucial for preclinical models, which have characteristic
patterns of Aβ deposition. In human Aβ-PET imaging, the whole
cerebellum and the cerebellar graymatter have been the preferred
reference regions for most large scale quantitative investigations
(Vandenberghe et al., 2010; Barthel and Sabri, 2011; Clark et al.,
2011). However, recent human studies with fluorinated amyloid
tracers have revealed longitudinal stabilization of standardized
uptake value ratios (SUVR), with use of white matter or brain
stem reference regions, this despite the ongoing accumulation
of Aβ plaques as confirmed by histology (Landau et al., 2014,
2015; Brendel et al., 2015a; Chen et al., 2015). There has so far
been no systematic comparison of scaling methods for mouse
Aβ-PET imaging. Consequently, we aimed to compare different
scaling methods and reference regions in a large series of
Aβ studies with [18F]-florbetaben (FBB) in an established AD
mouse model, with regard to accuracy of the PET method in
capturing longitudinal changes in Aβ-deposition, with terminal
histological plaque quantitation serving as the gold standard. The
overall aims of this study were to investigate if automated brain
spatial normalization is beneficial for quantitation of preclinical
Aβ-PET, and to identify an optimally performing method for
intensity scaling.
MATERIALS AND METHODS
Animal Model and Study Design
All experiments were performed in compliance with the
National Guidelines for Animal Protection, Germany, with
approval of the local animal care committee of the Government
of Oberbayern (Regierung Oberbayern), and overseen by a
veterinarian. Anesthesia was performed with isoflurane 1.5%.
Mice were killed by cervical dislocation in a state of deep narcosis.
The transgenic B6.PS2APP (line B6.152H) is homozygous
for both the human presenilin (PS) 2, N141I mutation and
the human amyloid precursor protein (APP) K670N, M671L
mutation. The APP and PS2 transgenes are driven bymouse Thy-
1 and mouse prion promoters, respectively. This line had been
created by co-injection of both transgenes into C57Bl/6 zygotes
(Richards et al., 2003). Homozygous B6.PS2APP mice show first
appearance of plaques in the cortex and hippocampus at 5–6
months of age (Ozmen et al., 2009).
Aβ-PET scans (N = 114) were used from two studies wherein
drug-naive longitudinal FBB-PET recordings were obtained in
PS2APP mice (N = 37) at a short interval (8 and 9.5 months
of age). Furthermore, we also used terminal Aβ-PET recordings
(N = 40; range: 13–16 months; N = 24 from the longitudinal
set and N = 16 from another historical investigation), in which
histologically quantified terminal plaque load was measured. We
defined the different ages for Aβ-PET imaging as “BL” for the
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baseline at 8months (N = 37 PS2APPmice), “FU” for the follow-
up of the same group at 9.5 months (N = 37 PS2APP mice), and
“TER” for the terminal Aβ-PET recordings obtained between 13
and 16 months of age (N = 40 PS2APP mice).
Radiochemistry
The [18F]-florbetaben precursor (Piramal Imaging, Berlin) was
radiolabeled by the method of Zhang et al. (2005), with slight
modifications. This procedure is described elsewhere (Rominger
et al., 2013), and yields a radiochemical purity exceeding 98% and
specific activity of 50–90 GBq/µmol at the end of synthesis.
Amyloid Pet Acquisition and
Reconstruction
Image acquisition and reconstruction followed a standardized
protocol (Brendel et al., 2015b). Mice were anesthetized with
isoflurane (1.5%, delivered via a mask at 3.5 L/min in oxygen)
and received bolus injection of 10.1 ± 2.3MBq of [18F]-
florbetaben in 150µL of saline to a tail vein. Following placement
in the tomograph (Siemens Inveon DPET), a single frame
emission recording for the interval 30–60min p.i. followed by a
15min transmission scan was obtained using a rotating [57Co]
point source. The image reconstruction procedure consisted of
an three-dimensional ordered subset expectation maximization
(OSEM) with four iterations and 12 subsets followed by a
maximum a posteriori (MAP) algorithm with 32 iterations.
Scatter and attenuation correction were performed and a decay
correction for [18F] was applied. With a zoom factor of 1.0 and
a128×128× 159 matrix, a final voxel dimension of 0.78×0.78×
0.80mm was obtained.
Image Analysis
Spatial Normalization
Aβ-PET images were first blinded to the reader by coding of
the Aβ-PET files. Images were coregistered to a 3T magnetic
resonance imaging (MRI) mouse brain template (Dorr et al.,
2007) by a rigid manual fusion, using the PMOD FUSION tool
(v. 3.4 PMOD Technologies, Zürich). The spatial normalization
was independently performed by an expert (>1000 fusions), an
experienced reader (∼150 fusions) as well as a novice reader
who had been trained for 4 h over the course of 2 days. The
expert fusion was repeated to assess test-retest variability (%) for
operators with high training level.
All spatial normalized images of the expert reader were
intensity scaled to the injected dose and multiplied by the
individual body weight to give standardized uptake value (SUV)
images. Then age-dependent groups (N = 37 or N = 40 images
each) from PS2APP mice were averaged for the generation of
three different templates defined at increasing stages of amyloid
pathology (Figure 1A).
Subsequently, fused images from all readers were spatially
normalized on all different templates by applying an automated
nonlinear transformation, which removed the main differences
in brain size and shape using the normalization algorithm
in SPM5 (Wellcome Department of Cognitive Neurology,
London, UK) implemented within the PMOD FUSION tool
(V. 3.4 PMOD Technologies, Zürich). This algorithm was set
to mouse brain dimensions using standardized settings (equal
modality; nonlinear warping; 16 iterations; frequency cutoff 3;
regularization 1.0; no thresholding). The procedure was tested
with and without transient input smoothing by applying a
0.6mm Gaussian to the image before initiation of warping
operations. The calculated transformation matrix was saved and
finally applied to the “raw” input image to avoid loss of resolution
due to repeated image resampling.
Inter-Reader Analyses
For inter-reader analyses, Fleiss Kappa (κ) was calculated for
TER results (SUVCTX and SUVRCTX/REF as described below)
from expert vs. experienced, experienced vs. novice, expert vs.
novice, both before and after automated brain normalization.
Furthermore, inter-reader variability (%) was calculated, and
compared to the expert test-retest variability (%). For statistical
testing of absolute differences for SUVCTX and SUVRCTX/REF
between different readers before and after brain normalization a
permutation test was performed as described in Section Statistics
below and was also used to test for significant differences between
inter-reader variability (%) and expert test-retest variability (%).
Analysis of Template Influence on Automated Brain
Intensity Normalization
To assess the impact of stage specific templates, TER results of
the expert before brain normalization were compared with TER
results after brain normalization to TER, FU, and BL templates by
calculation of error-(%), with findings of the expert considered
as the standard of truth. A paired t-test was used for statistical
testing of significant alterations in SUVCTX and SUVRCTX/REF (as
described below) resulting from different templates.
Scaling
A total of five intensity scaling methods were performed, all using
VOIs predefined in the final image space, which was identical
for MRI and [18F]-florbetaben templates. Beside calculation of
frontal cortical SUVCTX, we tested intensity scaling by four
different reference regions (Figure 1B):
1. Whole cerebellum (CBL) with a volume of 65mm3.
2. Hindbrain white matter (WM), including high unspecific
tracer retention areas (threshold-based) such as pons,
midbrain, cerebellar peduncle, cranial hypothalamus and
caudal thalamus, with a total volume of 67mm3.
3. Brainstem (BST), an oval shaped region extending from pons
to midbrain, with a volume of 24mm3.
4. Whole brain as the global mean (GLM), with a volume of
525mm3.
As target regions two bilateral frontal cortex VOIs comprising
12mm3 each (Figure 1A), were employed for calculation of
[18F]-florbetaben cortex-to-reference SUVRCTX/REF.
Longitudinal stability
Scaling methods were tested against each other by evaluating the
longitudinal stability of the endpoint (SUVCTX or SUVRCTX/REF)
over the brief 6 week interval from BL to FU in N = 37
animals. Pearson’s coefficients of correlation (R) were calculated
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FIGURE 1 | (A) [18F]-florbetaben PET templates at different pathology stages, deriving from mean findings in groups of PS2APP mice aged 8, 9.5, and 13–16
months. PET images are superimposed on an MRI-based mouse brain atlas (Dorr et al., 2007) for anatomical reference. The frontal cortical target VOI is depicted in
blue. (B) Reference region VOIs are illustrated on the same MRI mouse atlas; from top to bottom: cerebellum (blue; CBL), hindbrain white matter (orange; WM),
brainstem (red; BST), whole brain (green; GLM).
for SUVCTX and SUVRCTX/REF values of the four different
reference regions, given the assumption that the mouse model is
characterized by a nearly linear progression of amyloidosis over
time, as supported by findings from our previous study (Brendel
et al., 2015b). The variance of BL and FU groups, expressed by
SD-(%), was calculated as an indicator of intra-group stability.
Effect sizes (Cohen’s d) for the resulting differences between the
two sequential Aβ-PET scans were calculated as an additional
quality criterion in the longitudinal design.
Longitudinal regional analyses
To test the impact of different scaling methods for Aβ-PET on
the detected differences in longitudinal data independently from
the cortical target VOI, we assessed alterations in FBB-binding
between BL and FU voxel-wise by statistical parametric mapping
(SPM). We used SPM5 routines implemented in MATLAB
(version 7.1), adapted from Sawiak et al. (2009) for mouse data.
For SUVCTX and each reference region approach, we performed a
paired t-test for Aβ-PET images (FU vs. BL) of PS2APP (N = 37)
mice, and thus assessed increases or decreases over 6 weeks of
follow up.
Histochemical Analyses
Histochemical analyses were performed in a matching frontal
cortex region of interest as the gold standard of amyloid
burden, for evaluating reliability of frontal cortical SUVCTX and
four different SUVRCTX/REF results. The procedure followed
a standardized protocol wherein cortical plaque load (%)
was calculated for each animal (Brendel et al., 2015b). For
correlation analyses of the terminal Aβ-PET estimates (N =
40) with plaque load (%), Pearson’s coefficients of correlation
(R) were calculated with and without brain normalization and
for all different intensity normalization methods. Significant
differences between correlation coefficients before and after
spatial brain normalization, between different readers, and
between different intensity normalization methods were assessed
by an extended Fisher’s transformation approach as described in
Section Statistics.
Statistics
A permutation test was used to test for significance of not
normally distributed differences between two readers before
and after normalization and for the comparison of inter-
reader variability (%) with test-retest variability (%) of the
expert. Absolute values were used for these comparisons.
For permutation testing, the results were pooled and a loop
rearranging the pooled results into two groups (with 1 million
repeats) was coded within Matlab 7.12.0. The originally observed
results of difference between manually acquired and normalized
data or of difference between test-retest expert variability (%)
and inter-reader variability (%) were defined as target values. For
every resampled pair the mean result was calculated and each
mean result equal to or higher than the target value was counted
automatically. Finally, the total count was set in relation to the
number of repeats to obtain the p-value.
Significant differences between two dependent correlations
with one variable in common (plaque load %) were assessed
by an extended Fisher’s transformation approach (Lee and
Preacher, 2013). First, each correlation coefficient was converted
into a z-score using Fisher’s r-to-z transformation. Then,
asymptotic covariance of the estimates was computed. Finally,
these quantities were used in an asymptotic z-test. A threshold
of p < 0.05 was considered to be significant for rejection of the
null hypothesis in all statistical tests.
RESULTS
Spatial Normalization
Automated Brain Normalization Significantly
Reduces Inter-Reader Variability
The intra-reader test-retest variability of SUVRCTX/REF for the
expert reader was 1.4 ± 1.0% (range: 0.9–2.9% for different
reference regions). Inter-reader agreement for SUVRCTX/REF
was very high between the expert and the experienced reader
without brain pre-normalization (κ = 0.97 ± 0.02; inter-reader
variability 1.4 ± 0.8%), indicating a very high reproducibility
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FIGURE 2 | Bland-Altman plots of the inter-reader SUVRCTX/CBL(n = 40) agreement before (A,C) and after (B,D) brain spatial normalization. Difference
(y-axis) and mean (x-axis) between two readers are illustrated against each other, with the mean difference presented by the thick line and the upper (+1.96 SDs) and
lower limits (−1.96 SDs) of agreement by the dashed lines. Panels (A,B) show the comparison between expert and novice reader, while (C,D) show the relation
between expert and experienced reader.
when both readers are at a high training level without significant
differences when compared to the expert test-retest variability
(all p = n.s.). However, lower inter-reader agreement including
some strong outliers occurred between novice reader and expert
(κ = 0.89 ± 0.08; inter-reader variability 3.0 ± 1.8%; all p <
0.01), or novice and experienced reader (κ = 0.88 ± 0.06;
inter-reader variability 2.9 ± 1.5%; all p < 0.01). Especially
the agreement for SUVRCTX/CBL was lower in the latter two
contrasts (κ = 0.77/0.79; inter-reader variability = 5.6%/5.2%)
when only the manual PET-MRI fusions were compared. After
automated spatial brain normalization, all κ values were ≥ 0.99
and the maximal inter-reader variability was 0.6%. All differences
between readers were significantly lowered by the automated
brain normalization procedure (p < 0.001 for all reference
regions). Brain normalization without transient input smoothing
(0.6mm) during the automated coregistration process led to
some instances of strong image distortions, and was therefore
dismissed. Representative approximations of SUVRCTX/CBL
between readers after brain spatial normalization are illustrated
in Bland-Altman Plots (Figure 2) and all κ-values/%-variabilities
are reported in Table 1.
Template Characteristics Influence Brain
Normalization Results
FBB uptake in the TER scans was underestimated when
spatially normalized to templates from BL and FU disease
stages, under the assumption that the expert manual fusion
serves as the standard of truth. This effect was most obvious
with the cerebellum serving as the reference region (BL-
template: −0.6 ± 2.1%, p < 0.05/FU-template: −2.9 ± 2.4%,
p < 0.001; Figure 3A). With the stage specific TER template, low
SUVRCTX/REF values tended to be overestimated, whereas high
results were underestimated, but the mean error-(%) was only
±0.2%. Based on these findings, we attempted to quantify the bias
deriving from the deviation of individual SUVRCTX/REF from
the template SUVRCTX/REF by constructing a function defining
the relationship between error-(%) and the deviation-(%) =
(individual - SUVRCTX/REF-template-SUVRCTX/REF) / template -
SUVRCTX/REF
∗100. Using this function we estimated a bias
of ±13.8% (linear regression: R = −0.44; p < 0.01) for
SUVRCTX/CBL(Figure 3B), meaning that an individual mouse
with a 10% higher SUVRCTX/CBL compared to the template
results gives on average a 1.38% lower result after brain
intensity normalization. Respective bias was similarly high for
SUVRCTX/GLM (±10.1%; linear regression: R= −0.34; p < 0.05),
but distinctly lower for SUVRCTX/WM (±1.9%; linear regression:
R = −0.13; p = n.s.; Figure 3C) and SUVRCTX/BST (±1.7%;
linear regression: R = −0.16; p = n.s.). Absolute biases in
SUVRCTX/CBL and SUVRCTX/GLM were significantly higher
when compared to SUVRCTX/WM or SUVRCTX/BST (all
p < 0.001).
Longitudinal Analysis
Intracerebral Reference Regions give Lower Variance
and Higher Longitudinal Effect Sizes When
Compared to SUV
Implausibly low longitudinal increases of FBB binding were
obtained through generation of ordinary SUVCTX estimates
(R= −0.12, p= n.s.), which is explicable by the rather high
relative standard deviations in the BL (15.9%) and FU (13.2%)
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TABLE 1 | Inter-reader agreement.
κ/inter-reader variability (%) Test-retest variability
Reference Expert-experienced (κ/%) Experienced-novice (κ/%) Expert-novice (κ/%) Expert (%)
RAW FUSION
CBL 0.95/2.6 0.79/5.2* 0.77/5.6* 2.9
WM 0.98/1.0 0.91/2.4** 0.93/2.1** 0.9
BST 0.99/0.9 0.94/2.0** 0.96/1.8** 0.9
GLM 0.95/1.2 0.88/2.1** 0.89/2.3** 0.9
MEAN ± SD 0.97 ± 0.02/1.4 ± 0.8 0.88 ± 0.06/2.9 ± 1.5** 0.89 ± 0.08/3.0 ± 1.8** 1.4 ± 1.0
BRAIN NORMALIZATION
CBL 1.00/0.5 0.99/0.6 1.00/0.5
WM 1.00/0.2 0.99/0.4 0.99/0.4
BST 1.00/0.2 0.99/0.4 0.99/0.5
GLM 1.00/0.2 0.99/0.5 0.99/0.4
MEAN ± SD 1.00 ± 0.00/0.2 ± 0.1 0.99 ± 0.00/0.5 ± 0.1 0.99 ± 0.00/0.5 ± 0.1
Inter-reader agreement expressed by Fleiss κ and inter-reader variability (%) before and after brain normalization (BN) for all different reference regions. For the raw fusion the test-retest
variability of the expert is given. *p < 0.01; **p < 0.001 for interreader-variability (%) vs. expert test-retest variability (%), permutation test.
groups. Each of the four intracerebral reference regions stabilized
the Aβ-PET SUVRCTX/REF estimates, and resulted in distinctly
lower variance (2.3–4.6%), with highest agreement between BL
and FU for SUVRCTX/WM (R = 0.64, p < 0.001). Highest
effect sizes for the age-dependent increases were found with
SUVRCTX/WM and SUVRCTX/BST (d = 1.64), which exceeded
that for SUVRCTX/CBL (d = 1.23) and SUVRCTX/GLM (d = 1.21).
Details of this analysis are provided in Table 2.
Global Mean Scaling Gives Physiologically
Implausible Longitudinal Intensity Decreases in the
Hindbrain
Voxel-wise analyses revealed a longitudinal progression of
amyloidosis from BL to FU in the forebrain for all reference
regions in 648,691 voxels (CBL), 662,374 voxels (WM), 612,517
voxels (BST), and 47,247 voxel (GLM) (all FDR-corrected;
p < 0.05; Figure 4A). Together with the distinctly lower
number voxels with temporally increasing SUVR to GLM scaling,
156,066 voxels in the hindbrain (pons, midbrain, and cerebellum)
indicated an implausible decrease for SUVR from BL to FU
(FDR-corrected; p < 0.05; Figure 4B). No amyloid or vascular
pathology is known in these regions in PS2APP mice, nor
were there any plausible physiological or pathophysiological
explanations for a marked apparent decrease in the relative
decrease in the hindbrain Aβ-PET signal in a 6 weeks’ follow-up.
No significantly changing voxels were found when performing
SPM with raw SUV images.
Intensity Scaling by Intracerebral
Reference Regions Gives Superior
Agreement with Histology Compared to
SUV, and is Further Improved by
Automated Brain Spatial Normalization
The cortical plaque load (%) in N = 40 PS2APP aged 13–16
months mice was 10.8 ± 1.2%. The correlation between Aβ-PET
and plaque load (%) was poor (R ≤ 0.34, p < 0.05) for the case
of plain SUVCTX (Figure 5A), and consistent significantly lower
when compared to any intensity scaling to intracerebral reference
regions (all p < 0.001). SUVRCTX/REF estimates (Figure 5B)
revealed a high correlation (R ≥ 0.66, p < 0.001) with plaque
load (%) in this homogeneous sample of PS2APP mice regardless
of the operator training status, or application of automated brain
spatial normalization. Without automated brain normalization,
the correlation to histology of the manual coregistration by
the novice reader was significantly lower (Rmax = 0.70)
when compared to the expert (Rmax = 0.78; p < 0.01) or
experienced reader (Rmax = 0.76; p < 0.05). Application of
spatial brain normalization harmonized this correlation between
different readers (Rmax = 0.75–0.76; no significant differences
between readers). In this regard, manual coregistration by the
novice reader was significantly improved by automated brain
normalization (all reference regions: p < 0.05), whereas the
changes for the expert and experienced reader did not show any
significant alterations (all reference regions: p = n.s.). Scaling to
WM or GLM (Rmean = 0.75) was slightly superior (p = n.s.) to
BST (Rmean = 0.74) or CBL (Rmean = 0.73). All correlations are
provided in Table 3.
Best Global Performance is Archived by
Hindbrain White Matter Intensity Scaling
Based on the different analyses (brain normalization, group
analysis, longitudinal assessment, and correlation with histology
as the gold standard) we defined five categories, which need to
be addressed when considering the optimal intensity scaling for
[18F]-florbetaben Aβ-PET imaging in mice (Table 4). (1) The
impact of single animal results analyzed by templates used for
automated brain normalization should be minimal, but this was
not the case for cerebellar and global mean intensity scaling. (2)
Variance in groups of mice should not be artifactually raised
by the method, which was the case for raw SUVCTX. (3) The
effect sizes regarding longitudinal progression of amyloidosis
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FIGURE 3 | (A) SUVRCTX/CBL from N = 40 PS2APP mice aged 13–16 months after brain spatial normalization to a stage-specific (high) tracer uptake template
(TER-TEMPLATE, black-gray squares), an intermediate tracer uptake template (FU-TEMPLATE, red-purple diamonds) and a low tracer uptake template
(BL-TEMPLATE, blue triangles). Lower uptake templates gave systematic underestimation of SUVRCTX/CBLafter automated brain normalization when compared to
expert fusion. With the stage-specific template, minor underestimations were observed for high SUVRCTX/CBL and vice versa. Dashed line represents the line of
perfect identity (R = 1) between raw expert fusion and brain normalization). Significant differences (paired t-test) resulting from template mismatches vs. the stage
specific TER-template are indicated by *p < 0.05; **p < 0.001. Relationships between (%)-deviations of individual SUVRCTX/REF from the template SUVRCTX/REF and
the (%)-deviation of SUVRCTX/REF from the expert manual fusion after the brain normalization are illustrated for (B) the cerebellar and (C) the hindbrain white matter
reference region. Significant correlation is indicated by *p < 0.01.
TABLE 2 | Longitudinal 6-week follow-up.
BL MEAN BL SD (%) FU MEAN FU SD (%) d R
SUVCTX 0.48 0.08 (15.9%) 0.50 0.07 (13.2%) 0.23 −0.12
SUVRCTX/CBL 1.10 0.04 (3.6%) 1.16 0.05 (4.4%) 1.23 0.51
SUVRCTX/WM 0.92 0.03 (3.1%) 0.98 0.04 (4.1%) 1.64 0.64
SUVRCTX/BST 0.90 0.03 (3.6%) 0.96 0.04 (4.6%) 1.64 0.60
SUVRCTX/GLM 1.06 0.02 (2.3%) 1.10 0.04 (3.4%) 1.21 0.63
Results from the longitudinal 6 week follow-up in (N = 37) PS2APP mice. Mean cortical FBB PET values and their SD are given for BL and FU scans for the different scaling methods
together with the Cohen’s effect size (d) and BL-FU correlation (R).
in the frontal cortical target region should be captured as best
possible, which was the case for hindbrain white matter and
brainstem intensity scalings. (4) Longitudinal results should not
be affected by presence of amyloid pathology in the reference
region, which was the case for the global mean intensity scaling.
(5) Aβ-PET signal in single animals should correlate as best
possible with the histological gold standard, which was the case
for all intracerebral reference regions. There was trend toward
better agreement for hindbrain white matter and global mean
intensity scaling, compared to cerebellum or brainstem scaling.
Thus, in summary the hindbrain white matter scaling performed
best when considering the composite of factors.
DISCUSSION
We present a large-scale evaluation of automated spatial
brain normalization and a systematic comparison of different
intensity scaling methods for preclinical Aβ-PET imaging
with FBB. Our established Aβ-PET methodologies were
challenged by investigation of a homogeneous PS2APP
data set, including a short-term longitudinal follow-up, and
histologically validated gold standard results, all characterized
by a rather narrow range of plaque burden; this bodes well
for sensitive detection of treatment effects. Automated spatial
brain normalization reliably harmonized the results of different
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FIGURE 4 | Longitudinal changes in regional [18F]-florbetaben uptake in the short-term 6 week follow-up, study of (N = 37) PS2APP mice after intensity scaling to
the hindbrain white matter (A) and the global mean uptake (B) as assessed by SPM (FDR-corrected; p < 0.05; k < 20). T-contrasts expressing significant longitudinal
increases (yellow-red) and decreases (turquois-green) are projected upon sagittal slices of the MRI mouse brain atlas.
FIGURE 5 | Individual (A) SUVCTX and (B) SUVRCTX/REF PET correlations (expert manual fusion) with gold standard plaque load (%), as assessed by histochemistry,
in (N = 40) PS2APP mice aged 13–16 months, are illustrated for SUVCTX (purple circles) and the different reference regions, i.e., cerebellum (CBL, blue squares),
hindbrain white matter (WM, red diamonds), brain stem (BST, green circles), and global mean (GLM, orange triangle).
readers even if poorly trained, while the correspondence with
histological gold standard assessments remained stable or
even improved. Scaling by intracerebral reference regions
(SUVRCTX/REF) was distinctly superior to plain SUVCTX,
both with regard to longitudinal stabilization and agreement
with histology. Global mean intensity scaling revealed a
comparable correlation with histology when contrasted to
reference regions demonstrably devoid of Aβ pathology, but this
procedure impaired detection of longitudinal increases in Aβ
in cortex, and returned physiologically implausible decreases
in brain regions lacking Aβ burden. A hindbrain white matter
reference was slightly superior to the cerebellar reference due,
we suppose, to lesser bias from bone uptake and template
differences.
Automated Brain Normalization
While small animal Aβ-PET studies experienced growing interest
in the recent years the methodological tools used for their
interpretation were rather heterogeneous. Spatial normalization
has hitherto mostly been done on MRI templates (Poisnel et al.,
2012; von Reutern et al., 2013), or with a hybrid PET-CT
apparatus (Snellman et al., 2013). One previous investigation of
this type used SPM-based automated brain normalization (Rojas
et al., 2013), and in most studies, the tracer uptake was scaled to
a cerebellum reference region (Maeda et al., 2007; Kuntner et al.,
2009; Manook et al., 2012; Poisnel et al., 2012; Snellman et al.,
2013), although some have employed plain SUV for their analyses
(Waldron et al., 2015). However, with respect to the small effect
sizes to brief follow-up in AD mice, and the susceptibility of
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TABLE 3 | Histology agreement.
Reader Expert Experienced Novice
RAW/BN RAW BN RAW BN RAW BN
SUVCTX 0.34** 0.34** 0.34** 0.34** 0.32** 0.31**
SUVRCTX/CBL 0.76 0.75 0.76 0.74 0.66* 0.74
SUVRCTX/WM 0.78 0.76 0.76 0.76 0.69* 0.75
SUVRCTX/BST 0.74 0.74 0.74 0.73 0.70* 0.73
SUVRCTX/GLM 0.75 0.76 0.76 0.76 0.70* 0.75
Correlations (R) with plaque load (%) as assessed by histochemistry for expert,
experienced and novice reader for the different scaling methods before (RAW) and
after brain normalization (BN). Significant differences between correlation coefficients are
indicated for SUVCTX vs. any SUVRCTX/REF and for raw fusions vs. brain normalizations
of the same reader *p< 0.05; **p< 0.001.
TABLE 4 | Intensity scaling summary.
Template Variance Longitudinal Pathology Histology
affection effect size affection
SUVCTX o − − o −
SUVRCTX/CBL − + + o +
SUVRCTX/WM o + ++ o +(+)
SUVRCTX/BST o + ++ o +
SUVRCTX/GLM − + + − +(+)
Significant advantages (moderate: +, light green; large: ++, dark green)/disadvantages
(−, light red) of different SUVCTX and SUVR calculations are illustrated in five categories,
which are deemed relevant for analysis of [18F]-florbetaben measurements in the mouse
brain. “o” indicate neutral condition; bracketed “+” indicate a trend to advantage.
“Template affection” refers to results Section Template Characteristics Influence Brain
Normalization Results. “Variance” refers to result Section Intracerebral Reference Regions
give Lower Variance and Higher Longitudinal Effect Sizes When Compared to SUV.
“Longitudinal effect size” refers to result Section Intracerebral Reference Regions Give
Lower Variance and Higher Longitudinal Effect Sizes When Compared to SUV. “Pathology
affection” refers to result Section Global Mean Scaling Gives Physiologically Implausible
Longitudinal Intensity Decreases in the Hindbrain. “Histology” refers to result Section
Intensity Scaling by Intracerebral Reference Regions Gives Superior Agreement with
Histology Compared to SUV, and is Further Improved by Automated Brain Spatial
Normalization.
our SUVCTX results to methodological inaccuracies, it is crucial
that Aβ-PET data be analyzed with robust, reliable and reader-
independent strategies, so as to ensure accuracy of the study
outcomes.
To our knowledge there have not been any studies
systematically investigating the inter-reader variability as a
limitation of small animal Aβ-PET studies, or indeed for any
other classes of radioligand. Our investigations were able to
show that manual coregistration of Aβ-PET images contributes
substantially to variation of results between readers, especially
when they have less experience. A further disadvantage of a
manual approach arises from the blinding which is necessary for
preclinical drug trials (Jucker, 2010). Thus, an experienced reader
is usually able to visually identify animals with different extent of
the Aβ pathology. So even if differing groups are blinded to the
reader, the visual impressions of the images potentially influence
the reader. The automated brain normalization diminishes the
impact of these influences toward zero as SUVRCTX/REF values
show nearly perfect inter-reader agreement after processing as
inter-reader differences were significantly lowered by the method
(Figure 2). Thus, the brain normalization brings about a pseudo-
blinding for small animal Aβ-PET analysis, and guarantees
minimization of inter-reader variance.
While aiming to improve the inter-reader agreement, the
automated brain normalization method should not reduce
the ultimate correlation between the PET endpoint with the
histological gold standard of amyloid burden. Our results
clearly indicate that correlation coefficients of PET results with
plaque burden remain equal after brain spatial normalization
for well-trained readers, whereas the agreement between PET
and histology is significantly improved for less trained operators
(Table 3): this is an important precondition for stable results in
longitudinal or multicentre studies.
We also observed an effect of applying Aβ-PET templates at
different pathology stages. Although this effect was never more
than 2.9% of the group mean, this avoidable systematic error
could potentially bias Aβ-PET outcomes in treatment studies
with small effect sizes (Balducci et al., 2014; Brendel et al.,
2015c). This bias of inappropriate templates is unsurprising,
as automated brain normalization orientates mainly at edges
and high uptake regions of the image (Gispert et al., 2003).
High plaque burden in the forebrain results in a cortical hot-
spot and sharper cortex-to-extracortical contrasts for Aβ-PET
mouse brain images, which influences the quality of spatial
normalization when this hot region is absent from the utilized
template or vice versa. In practice, this mismatch tends to
shrink the scaled PET image, leading to underestimation in
mice with higher plaque burden than in the template and an
overestimation in mice with lower plaque burden. Interestingly
SUVRCTX/WM and SUVRCTX/BST suffered a lower bias (<2%
relative to the deviation of the individual Aβ-PET image to its
template) when compared to SUVRCTX/CBL and SUVRCTX/GLM
(>10% relative to the deviation of the individual Aβ-PET to
its template), supporting the preferred use of the WM and
BST reference regions (Figure 3), with matching of stage/age.
Furthermore, transient smoothing of the input image with a
0.6mm filter proved indispensable to avoid strong distortions in
the automated spatial normalization.
Intensity Scaling Methods
Variance of plain SUVCTX was rather high in BL and FU groups
of this investigation (15.9/13.2%), thus indicating inadequate
intensity scaling of Aβ-PET images by this method. Well-
known sources of error in the SUVCTX calculation include
paravenous leakage of the injectate, variability in brain perfusion,
and imprecise measurement of radiotracer dosage. We typically
calculate injected dose by well-counting syringes before and after
tracer application, whereas measurement of the injected dose in
a whole body VOI can be more precise (Rominger et al., 2013).
However, our scanning configuration does not always capture the
entire body of the mice. While SUV measurements are improved
with arterial blood sampling, this is inherently linked with a high
logistic and economic effort, scarcely feasible in a longitudinal
setting. Our SUVCTX findings were distinctly inferior to the
several SUVRCTX/REF results, with respect both to longitudinal
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and histological validation analyses. Thus, SUV methods are not
to be recommended for preclinical Aβ-PET studies.
Having ascertained the need to make SUVR calculations,
we need to identify the optimal reference region for intensity
scaling. Since a whole brain VOI is easily obtained, scaling to
the global mean brain uptake is convenient. Indeed we find
a high correlation between SUVRCTX/GLM and the histological
gold standard of Aβ accumulation. However, when large parts of
the brain are affected by the amyloid pathology, the denominator
for scaling is of course raised by the high tracer retention.
This resulted in the spurious detection of declining relative
FBB uptake in the hindbrain to follow-up at 6 weeks, an
artifact that could mimic a real clearance of fibrillar Aβ in
longitudinal interventional designs. Furthermore, global mean
scaling attenuated the apparent cluster size and effect size for
increases in Aβ in the longitudinal part of the study, relative to
findings with scaling to reference regions expected to be devoid
of Aβ pathology. Our findings are supported by earlier [18F]-
FDG-PET investigations of metabolic rate in human brain, in
relation to artifactual findings arising as a consequence of global
normalization (Borghammer et al., 2009). Scaling to [18F]-FDG
uptake in a reference cluster unaffected by pathology clearly
improved the detection of zones of true hypometabolism in
patients with AD or fronto-temporal dementia (Yakushev et al.,
2009; Dukart et al., 2013). Thus, we are confident that scaling by
reference regions devoid of plaque pathology should perform best
for detection of Aβ in the present mouse study.
In most transgenic mouse models, the hindbrain remains
relatively unaffected by Aβ plaque accumulation (Teipel et al.,
2011), but due to the characteristically high retention of [18F]-
labeled Aβ tracers in white matter, the binding in hindbrain
regions is quite heterogeneous. With regard to FBB-PET, we
see low non-specific binding in the cerebellum (Rominger
et al., 2013), which led to our adoption of cerebellum as a
reference region in small animal Aβ-PET analysis for this and
related ligands (Manook et al., 2012). While the cerebellum
can serve as an accurate reference region, it remains vulnerable
to spill-in from the overlying cranium and adjacent vascular
structures (Mille et al., 2012). In addition, cerebellum VOIs
are at risk for contamination from non-cerebral voxels, if the
caudal border of the brain is not captured precisely. Together,
these factors probably account for instances of false high and
false low SUVRCTX/CBL; resultant higher variance especially
in longitudinal analyses of SUVRCTX/CBL are responsible for
the lower correlation between BL and FU in the present
longitudinal arm, as compared to the more precise findings with
SUVRCTX/WM or SUVRCTX/BST. While spill-over and imperfect
capture of the caudal brain edges are less of an issue for human
Aβ-PET, WM reference scaling seems to give more stable results
to follow-up than does cerebellum scaling (Chen et al., 2015;
Brendel et al., 2015a). Similarly, the highest effect size (d =
1.64) in the present 6-week longitudinal setting was observed for
SUVRCTX/WM and SUVRCTX/BST.
The whole point of Aβ-PET is to depict accurately the plaque
load.We designed the present study to test the limits of sensitivity
of the method, by examining reference tissue methods in a
cohort of PS2APPmice with rather narrow inter-individual range
in plaque load (8.6–13.9%). This is in comparison to the ten-
fold range used in previous mouse studies of the correlation
between Aβ-PET and histological plaque load (1.0–9.2%, 0.3–
13.3%; Manook et al., 2012; Rominger et al., 2013). Results
with all intracerebral reference regions correlated highly with
the histological gold standard, although WM normalization
gave a slightly higher correlation. The slight superiority of
SUVRCTX/WM over SUVRCTX/BST can be explained by the larger
volume, giving less statistical noise in the results. The slight
superiority of SUVRCTX/WM over SUVRCTX/CBL, attributed
above to imperfect delineation of the caudal limit of the brain, is
also demonstrated by the lower correlation of SUVRCTX/CBL by
the novice reader with histology (R = 0.66); visual interpretation
of caudal limit of the fusion images is a matter of skill-learning.
In summary, SUVRCTX/WM performed best for the detection
of Aβ by PET in transgenic mice, which should prove
advantageous in preclinical imaging studies of longitudinal
design (Table 4). Thus, quantitation of [18F]-florbetaben uptake
in interventional trials, where accurate monitoring in single
animals is mandatory, can be improved implementing hindbrain
white matter intensity scaling, in conjunction with automated
spatial normalization.
Limitations
As mentioned above, we did not use the best possible means to
measure the injected FBB dose; we suppose that whole mouse
VOIs would have propagated to better correlations of SUVCTX
with the histological gold standard. While our PS2APP mice are
characterized by almost complete absence of Aβ pathology in the
hindbrain, present findings are not translatable to mouse models,
which may express relevant Aβ plaque burden in the reference
regions tested in this paper. Thus, prior knowledge about
the regional deposition of Aβ is indispensable for appropriate
selection of the reference in preclinical Aβ-PET studies with FBB
or related tracers.
Excessive reliance on automated methods for spatial
normalization of mouse brain should be avoided. Although
we did not detect any failures of the method, they might still
occur, were artificial hot spots present in the image. Thus, we
saw distinctly more cases of image distortions, especially in
brains with more heterogenous FBB uptake, in the absence of
transient input smoothing. As in all PET studies, it is important
to visually control post-processed images for potentially failed
spatial normalizations. In consideration of this issue, we first
attempted automated brain normalization with larger templates
(data not shown) encompasing adjacent extracerebral regions, so
as to support a correction of effects of partial volume (Brendel
et al., 2014). This approach yielded some excessive distortions
of the brain, when the VOI extended to include sources in the
neck or spine. We note that templates fulfilling the differing
requirements for partial volume effect correction and automated
brain normalization remain to be validated.
CONCLUSION
Automated spatial normalization of mouse brain can be applied
to Aβ-PET studies with FBB, thus ensuring pseudo-blinding,
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and by eliminating inter-reader variability due to differing skill
learning. This improves the reproducibility of the endpoint,
even if the reader is poorly trained. Intracerebral reference
regions lacking Aβ pathology are necessary for accurate in vivo
quantification of Aβ-PET with FBB; use of a hindbrain WM
reference tissue gave the best performance predominately due
to advantages in longitudinal designs. SUVCTX generation and
global mean scaling were distinctly inferior in performance to
the intensity scaling by pathology-free intracerebral reference
regions.
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